JUPITER Study: Transapical Aortic Valve Implantation for Aortic Regurgitation

NCT ID: NCT01598844

Last Updated: 2020-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

210 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-05-30

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this registry is to observe longterm performance and safety of the JenaValve TAVI system, in routine medical and everyday conditions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to evaluate the long term safety and effectiveness of the CE-marked JenaValve System Transapical in an elderly patient population with severe aortic stenosis and/or aortic insufficiency who are at high risk for open surgical aortic valve replacement.

The target study population will consist of elderly patients suffering from severe symptomatic degenerative aortic valve stenosis and/or aortic insufficiency who show an increased risk for an open aortic valve replacement surgery due to existing co-morbidities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Stenosis Aortic Insufficiency Aortic Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High risk patients with aortic stenosis

Transapical aortic valve implantation using a transcatheter heart valve for aortic stenosis.

Transcatheter aortic valve replacement

Intervention Type DEVICE

Transcatheter aortic valve replacement via a transapical access

High risk patients with AI

Transapical aortic valve implantation using a transcatheter heart valve for aortic regurgitation.

Transcatheter aortic valve replacement

Intervention Type DEVICE

Transcatheter aortic valve replacement via a transapical access

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcatheter aortic valve replacement

Transcatheter aortic valve replacement via a transapical access

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

The JenaValve TAVI System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients suitable for TAVI with the JenaValve according to instructions for use

Exclusion Criteria

* Patients unsuitable for TAVI with the JenaValve according to instructions for use
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

King's College London

OTHER

Sponsor Role collaborator

Universitätsklinikum Hamburg-Eppendorf

OTHER

Sponsor Role collaborator

JenaValve Technology, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Olaf Wendler, Prof

Role: PRINCIPAL_INVESTIGATOR

King's College Hospital NHS Trust

Hendrik Treede, Prof

Role: PRINCIPAL_INVESTIGATOR

University Heart Center Hamburg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Herz- und Diabeteszentrum NRW

Bad Oeynhausen, , Germany

Site Status

Herzzentrum der Universität

Cologne, , Germany

Site Status

Herzzentrum Dresden, Universitätsklinik an der Technischen Universität Dresden

Dresden, , Germany

Site Status

University Hospital

Erlangen, , Germany

Site Status

University Heart Centre

Freiburg im Breisgau, , Germany

Site Status

Asklepios Klinik

Hamburg, , Germany

Site Status

Universitäres Herzzentrum Hamburg

Hamburg, , Germany

Site Status

Herzzentrum Leipzig - Universitätsklinik

Leipzig, , Germany

Site Status

Deutsches Herzzentrum München

Munich, , Germany

Site Status

Herzzentrum des Städtischen Klinikums München

Munich, , Germany

Site Status

Herz- und Kreislaufzentrum Rotenburg (Fulda)

Rotenburg an der Fulda, , Germany

Site Status

Robert Bosch Krankenhaus Stuttgart

Stuttgart, , Germany

Site Status

St. Antonius Ziekenhuis

Nieuwegein, , Netherlands

Site Status

Universitätsspital Basel

Basel, , Switzerland

Site Status

King's College Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany Netherlands Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Mieres J, Menendez M, Fernandez-Pereira C, Rubio M, Rodriguez AE. Transapical Implantation of a 2nd-Generation JenaValve Device in Patient with Extremely High Surgical Risk. Case Rep Cardiol. 2015;2015:458151. doi: 10.1155/2015/458151. Epub 2015 Aug 4.

Reference Type BACKGROUND
PMID: 26346128 (View on PubMed)

Seiffert M, Bader R, Kappert U, Rastan A, Krapf S, Bleiziffer S, Hofmann S, Arnold M, Kallenbach K, Conradi L, Schlingloff F, Wilbring M, Schafer U, Diemert P, Treede H. Initial German experience with transapical implantation of a second-generation transcatheter heart valve for the treatment of aortic regurgitation. JACC Cardiovasc Interv. 2014 Oct;7(10):1168-74. doi: 10.1016/j.jcin.2014.05.014. Epub 2014 Aug 13.

Reference Type BACKGROUND
PMID: 25129672 (View on PubMed)

Silaschi M, Treede H, Rastan AJ, Baumbach H, Beyersdorf F, Kappert U, Eichinger W, Ruter F, de Kroon TL, Lange R, Ensminger S, Wendler O. The JUPITER registry: 1-year results of transapical aortic valve implantation using a second-generation transcatheter heart valve in patients with aortic stenosis. Eur J Cardiothorac Surg. 2016 Nov;50(5):874-881. doi: 10.1093/ejcts/ezw170. Epub 2016 May 30.

Reference Type RESULT
PMID: 27242354 (View on PubMed)

Silaschi M, Conradi L, Wendler O, Schlingloff F, Kappert U, Rastan AJ, Baumbach H, Holzhey D, Eichinger W, Bader R, Treede H. The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation. Catheter Cardiovasc Interv. 2018 Jun;91(7):1345-1351. doi: 10.1002/ccd.27370. Epub 2017 Nov 24.

Reference Type RESULT
PMID: 29171730 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

JV03PMS

Identifier Type: -

Identifier Source: org_study_id